Goserelin

(Zoladex®)

Zoladex®

Drug updated on 10/23/2023

Dosage FormImplant (subcutaneous: 10.8 mg)
Drug ClassGonadotropin releasing hormone (GnRH) agonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For use in combination with flutamide for the management of locally confined carcinoma of the prostate.
  • For use as palliative treatment of advanced carcinoma of the prostate.

Product Monograph / Prescribing Information

Document TitleYearSource
Zoladex (goserelin) Prescribing Information.2020TerSera Therapeutics LLC, Deerfield, IL

Systematic Reviews / Meta-Analyses